T1	Claim 1 129	Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC).
T2	Claim 130 229	Some studies have also suggested that gemcitabine is well tolerated and effective in such patients.
T3	Premise 1152 1235	Compared with each single drug, the combination treatment did not improve survival.
T4	Premise 1236 1477	The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine.
T5	Premise 1478 1547	Although quality of life was similar across the three treatment arms,
T6	Premise 1548 1621	the combination treatment was more toxic than the two drugs given singly.
T7	Claim 1622 1794	The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.
R1	Partial-Attack Arg1:T5 Arg2:T6	
R2	Support Arg1:T4 Arg2:T7	
R3	Support Arg1:T3 Arg2:T7	
R4	Support Arg1:T6 Arg2:T7	
